The NOVA study is aimed at assessing the efficacy of Natalizumab (Tysabri) in Multiple Sclerosis patients at an interval of 6 weeks between doses, in contrast with the traditional 4 week interval. We will be accepting new volunteers until June of 2020. Since the advent of new therapies, it is important to investigate if new patients benefit from the older, milder therapies or if the risk of relapse and disability are best addressed with stonger therapies early in the disease course.Įnrollment Information: The TREAT-MS study follows volunteer patients for the first few years of their MS therapy, and tracks their disease progression, disability risk and satisfaction. In the last few decades, we have developed new, stronger and more aggressive therapies to prevent relapse and disability in MS. We are working with Johns Hopkins University and the Patient Centered Outcomes Research Institute (PCORI) to help identify the most efficacious treatment strategies for relapsing-remitting Multiple Sclerosis. This database study will help us see how MS impacts our patient population as a whole, which may lead to a better understanding of MS disease course and treatment.Įnrollment Information: This study is actively recruiting patients with MS or a related disease. TRAC MS, or The Repository of Advanced Clinical Metrics in MS, is a research study that aims to find out more about the development, diagnosis, treatment and long-term outcomes of MS and related diseases. This study aims to identify potential pathways through which relapsing forms of MS advance into progressoive forms of MS.Įnrollment Information: This study consists of a single blood-draw, and is now actively recruiting both MS and healthy control participants. Our BioAging study investigates the association of biological aging of senescenct cells and aging in multiple sclerosis patients. This study aims to understand how the environment influences MS risk, by studying microbiome of MS patients in comparison to their healthy cohabitants.Įnrollment Information: We are collecting stool and blood samples from MS patients and a genetically unrelated healthy counterpart living in the same household (i.e a spouse, roommate or adoptive parent). One standout environmental factor is the microbiome, or the genetic material of bacteria inside the GI tract. The cause of Multiple Sclerosis is yet unclear, but it is evident that it includes a combination of genetic factors and environmental factors. Our neuroimmunology team is participating in the International Multiple Sclerosis Microbiome Study (iMSMS). International Multiple Sclerosis Microbiome Study If you are interested in learning more, contact Annalise Miner.
Octave bioscience trial#
Participation in this trial includes access to the Octave Care mobile app, as well as the completion of blood-draws and questionnaires over a 12-month period.Įnrollment Information: This study is currently open for enrollment to MS patients. The MOVING MS study investigates the impact of a Care Platform, complete with medication and symptom tracking, as well as access to a Care Partner, on patient satisfaction and healthcare utilization. in order to implement their Octave Care Platform in a research trial.
Our research group has collaborated with Octave Bioscience Inc. Currently Enrolling Studies MOVING MS Study
With a commitment to bring new therapies to our patients, we run a clinical trials program for MS and related diseases.